Fairvalue-Calculator Fairvalue-Calculator
EN DE

HOYA Corporation (HOCPY) Fair Value & Analysis

Healthcare · US · Market cap $59.7B

Price$162.33
Fair Value$101.00
Upside-37.8%
Quality95/100
Evidence: High Range $67.54 – $126.57

Analysis

HOYA Corporation (HOCPY) currently trades at $162.33, while our model-based Fair Value estimate is $101.00 — implying the stock looks roughly 37.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

HOYA Corporation, a med-tech company, provides high-tech and medical products in the Japan, Asia, the Americas, Europe, and internationally. The company operates through two segments: Life Care, and Information and Communications. It offers life care products, including eyeglasses; contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics, brain surgery, and dentistry. The company also operates Eyecity, a specialty retailer of contact lenses. In addition, it provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging related products that comprise optical glasses/optical lenses, colored glass filters, and UV light resources. Further, the company engages in research, development, manufacture, and sale of …

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -62% EssilorLuxottica Société anonyme (ESLOF) -34% Medline Inc (MDLN) -15% Becton, Dickinson and Company (BDX) -22% Alcon Inc (ALC) -44% ResMed Inc (RSMDF) +23%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.